Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

HLD-200: Phase III started

September 7, 2015 7:00 AM UTC

Highland began the double-blind, placebo-controlled, U.S. Phase III AHEAD trial to evaluate 40, 60 or 80 mg oral HLD-200 once daily for 3 weeks in about 140 patients ages 6-12. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article